The United Kingdom and the United States have signed a major trade agreement that will preserve zero levies on UK drug products entering the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to boost expenditure on medicines through the public health system. This move ensures that import taxes on these vital exports will be held at nothing for a timeframe of three years.
This agreement follows earlier statements to significantly raise tariffs on patented pharmaceutical products, with increases floated as high as double the cost.
"This agreement between the Britain bolsters the worldwide climate for innovative medicines and introduces long-overdue balance to transatlantic drug exports," a statement said.
Commercial Impact
Pharmaceuticals are one of the the United Kingdom's most significant export categories to the United States, which is easily the primary buyer for leading companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months to the end of last September, the UK sold drugs valued at over eleven billion pounds to the US. This value made up 17.4% of British export trade in that period.
"This agreement safeguards jobs, stimulates funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The deal entails several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to control costs will be limited at 15%. Previously, rebates exceeded twenty percent.
Broader Context
The pact follows a long-running row between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were intensified by assertions that US consumers were paying several times more for the equivalent treatments than consumers in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been announced toward projects in the United States.
A senior figure acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a share of its total funding over the last ten years.
